GSK and S&P 500 Performance During 2007-08 Crisis. GSK stock declined from $53 in September 2007 (pre-crisis peak) to around $28 in March 2009, as the markets bottomed out, implying it lost 48% of ...

The pharmaceutical company said it remained confident in the benefit and risk profile of Blenrep and will continue to work ...

GSK (GSK) closed the latest trading day at $36.98, indicating a +0.65% change from the previous session's end. This change outpaced the S&P 500's 0.27% gain on the day. Elsewhere, the Dow gained 0 ...

Additionally, GSK has a PEG Ratio of 1.2 and a Price/Cash Flow ratio of 7.3X. Value investors should also note GSK's Price/Sales ratio of 2X. A company's earnings performance is important for ...

Stock to Watch: GSK (GSK) ... Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. ... more than double the S&P 500's performance.

To begin my analysis, looking at GSK's most recent earnings report, Q3 2023 demonstrates a robust financial performance. Their Q3 revenue reached approximately $9.939B, reflecting a 10% increase ...

GSK PLC closed 19.70% below its 52-week high of £16.79, which the company achieved on September 9th.

In the segment, while products like Nucala and Dovato are key top-line drivers, new long-acting HIV medicines, Cabenuva and ...

Additionally, GSK has a PEG Ratio of 1.3 and a Price/Cash Flow ratio of 6.8X. Value investors should also note GSK's Price/Sales ratio of 1.9X. A company's earnings performance is important for ...

We recently published a list of 8 Most Undervalued Healthcare Stocks to Buy According to Analysts. In this article, we are going to take a look at where GSK plc (NYSE:GSK) stands against other ...

GSK settles U.S. Zantac lawsuit, avoiding trial. Confidential settlements reinforce commitment to legal efficiency.